Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 93

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 93
---
 -ownedsubsidiary of NLS for the purpose of effecting the Merger and to serve as the vehicle for, and to be subsumed by, Kadimastem pursuant to the Merger. 1 Kadimastem Kadimastem is a clinical -stagepharmaceutical company focused on developing and manufacturing “off -the-shelf” allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells, or hESCs, into functional cells. Kadimastem is primarily developing two products: 1.AstroRx ®, Kadimastem’s lead product, which is an off -the-shelfcryopreserved cell therapy product in clinical development for the treatment for ALS and in pre -clinicalstudies for other neurodegenerative indications. AstroRx ®is comprised of fully differentiated astrocytes, which are mainly cells that support the CNS. 2.IsletRx is Kadimastem’s treatment for diabetes is currently in preclinical development. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with Type 1 diabetes and possibly Type 2 insulin dependent diabetes. The IsletRx development program includes three programs in various preclinical development stages; iTOL -102(Pre -IND), Encap -IsletRx(INTERACT) and In -Scaffold-IsletRx(early development). Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif ®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is currently listed on the TASE (TASE: KDST). Kadimastem’s principal offices are located at Pinchas Sapir3, Weizmann Science Park, Ness -Ziona, Israel. General Description of the Merger and the Merger Agreement (Pages 126 and 144) The terms and conditions of the Merger are contained in the Merger Agreement, a copy of which is attached as Annex A to this proxy statement/prospectus. You are encouraged to read the Merger Agreement carefully and in its entirety, as it is the primary legal document that governs the Merger. Pursuant to the Merger Agreement: (i) Merger Sub will merge with and into Kadimastem